A. Erhardt

Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

Julia Dietz, Christiana Graf, Christoph P. Berg, Kerstin Port et autres

Background and Aims: Data on the prevalence and characteristics of so-called rare HCV genotypes (GTs) in larger cohorts is limited. This study investigates the frequency of rare GT and resistance-associated substitutions and the efficacy of retreatment in a European cohort. Methods: A …

de, be, ch (code pays fourni par la source)

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

Julia Dietz, Beat Müllhaupt, Peter Buggisch, Christiana Graf et autres

de (code pays fourni par la source)

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

Julia Dietz, Ulrich Spengler, Beat Müllhaupt, Julian Schulze zur Wiesch et autres

de, ch, at (code pays fourni par la source)

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

Julia Dietz, S. Süsser, Johannes Vermehren, Kai‐Henrik Peiffer et autres

de, at, es, hu (code pays fourni par la source)

Hepatitis B

Tobias Heintges, Dieter Häussinger, W.O. Böcher, A. Erhardt et autres

HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis

A. Erhardt, A. Maschner-Olberg, C. Mellenthin, G. Kappert et autres